Goodlukast LC Tablet contains Levocetirizine 5mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist for the effective management of allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a selective leukotriene D4 receptor antagonist, prevents leukotriene-mediated bronchoconstriction, inflammation, and mucus production, making it beneficial in the prophylaxis and chronic treatment of asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Goodlukast LC is indicated for patients with seasonal or perennial allergic rhinitis, chronic idiopathic urticaria, and as adjunctive therapy in asthma management to improve pulmonary function and reduce exacerbations. It is generally well-tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal discomfort. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision, especially in pediatric and elderly populations. Goodlukast LC Tablet offers a convenient once-daily dosing regimen, enhancing patient compliance in the management of allergic disorders.